The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States

References

• Gruber S, Lezcano B, Hylland S. Rheumatoid arthritis. In: DiPiro JT, Yee GC, Posey LM, et al. editors. Pharmacotherapy: a pathophysiologic approach. 11th ed. McGraw Hill: 2020:1517–1536.
   Google Scholar
• Centers for Disease Control and Prevention. Rheumatoid arthritis (RA). [cited 2020 Sep 29]. [Internet]. Available from: https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735.
   PubMed Web of Science ®Google Scholar
• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22:1–12.
   PubMed Web of Science ®Google Scholar
• Ekwall A-KH, Firestein GS. Rheumatoid arthritis: clinical manifestations and diagnosis. In: Burakoff R, editor. Decker: medicine. Philadelphia [PA]: Decker Intellectual Properties; 2021.
   Google Scholar
• Testa D, Calvacchi S, Petrelli F, et al. One year in review 2021: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2021;39:445–452.
   PubMed Web of Science ®Google Scholar
• Silvagni E, Sakellariou G, Bortoluzzi A, et al. One year in review 2021: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2021;39:705–720.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22:10–18.
   PubMed Web of Science ®Google Scholar
• Deane KD, Holers VM. Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol. 2021;73:181–193.
   PubMed Web of Science ®Google Scholar
• El Jammal T, Sève P, Gerfaud-Valentin M, et al. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. Expert Opin Pharmacother. 2021;22:205–218.
   PubMed Web of Science ®Google Scholar
• Schett G, Tanaka Y, Isaacs JD. Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nat Rev Rheumatol. 2021;17:135–144.
   PubMed Web of Science ®Google Scholar
• George G, Shyni GL, Raghu KG. Current and novel therapeutic targets in the treatment of rheumatoid arthritis. Inflammopharmacology. 2020;28:1457–1476.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73:924–939.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26. 2015.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Davis J, Matteson EL, et al. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis. 2020;79:440–444.
   PubMed Web of Science ®Google Scholar
• Ekwall A-KH, Firestein GS. Rheumatoid arthritis: etiology and pathogenesis. In: Burakoff R, editor. Decker: medicine. Philadelphia [PA]: Decker Intellectual Properties; 2021.
   Google Scholar
• Kawatkar AA, Jacobsen SJ, Levy GD, et al. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the Medical Expenditure Panel Survey. Arthritis Care Res (Hoboken). 2012;64:1649–1656.
   PubMed Web of Science ®Google Scholar
• Williams EM, Walker RJ, Faith T, et al. The impact of arthritis and joint pain on individual healthcare expenditures: findings from the Medical Expenditure Panel Survey (MEPS), 2011. Arthritis Res Ther. 2017;19(1):38. 2011.
   PubMedGoogle Scholar
• Murphy LB, Cisternas MG, Pasta DJ, et al. Medical expenditures and earnings losses among US adults with arthritis in 2013. Arthritis Care Res (Hoboken). 2018;70:869–876.
   PubMed Web of Science ®Google Scholar
• Nair K, Ghushchyan V, Naim A. Effectiveness and costs of TNF-alpha blocker use for patients with rheumatoid arthritis. Am Health Drug Benefits. 2013;6:126–136.
   PubMedGoogle Scholar
• Patel A, Heslin M, Scott DL, et al. Cost-effectiveness of combination disease-modifying antirheumatic drugs versus tumor necrosis factor inhibitors in active rheumatoid arthritis: a pragmatic, randomized, multicenter trial. Arthritis Care Res (Hoboken). 2020;72:334–342.
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR, da Silva MRR, Almeida AM, et al. Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Rev Pharmacoecon Outcomes Res. 2021;21:1011–1016.
   PubMed Web of Science ®Google Scholar
• Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. Am Health Drug Benefits. 2017;10:27–36.
   PubMed Web of Science ®Google Scholar
• Medical Expenditure Panel Survey background. [Internet]. [cited 2022 Jun 23]. Available from: https://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp.
   Google Scholar
• Liu J, Yu F, Song L. A systematic investigation on the research publications that have used the Medical Expenditure Panel Survey (MEPS) data through a bibliometrics approach. Library Hi Tech. 2020;38:705–721.
   Web of Science ®Google Scholar
• Zuvekas SH, Olin GL. Validating household reports of health care use in the Medical Expenditure Panel Survey. Health Serv Res. 2009;44:1679–1700.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. International classification of diseases, (ICD-10-CM/PCS) transition – background. [Internet]. 2015 [cited 2021 Oct 25]. Available from: https://www.cdc.gov/nchs/icd/icd10cm_pcs_background.htm.
   Google Scholar
• Centers for Disease Control and Prevention. International classification of diseases, tenth revision, clinical modification (ICD-10-CM). [Internet]. 2021 [cited 2021 Oct 25]. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm.
   Google Scholar
• Mukherjee K, Kamal KM. Sociodemographic determinants of out-of-pocket expenditures for patients using prescription drugs for rheumatoid arthritis. Am Health Drug Benefits. 2017;10:7–15.
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• Southern DA, Quan H, Ghali WA. Comparison of the elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care. 2004;42:355–360.
   PubMed Web of Science ®Google Scholar
• McCormick N, Wallace ZS, Sacks CA, et al. Decomposition analysis of spending and price trends for biologic antirheumatic drugs in medicare and medicaid. Arthritis Rheumatol. 2020;72:234–241.
   PubMed Web of Science ®Google Scholar
• Dalal DS, Zhang T, Shireman TI. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2020;50:822–826.
   PubMed Web of Science ®Google Scholar
• Erath A, Dusetzina SB. Assessment of expected out-of-pocket spending for rheumatoid arthritis biologics among patients enrolled in Medicare Part D, 2010-2019. JAMA Network Open. 2020;3:e203969.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Caporali R, Doerner T, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. RMD Open. 2021;7:e001637.
   PubMed Web of Science ®Google Scholar
• Chen AJ, Gascue L, Ribero R, et al. Uptake of infliximab biosimilars among the Medicare population. JAMA Intern Med. 2020;180:1255.
   PubMed Web of Science ®Google Scholar
• FDA Purplebook . [Internet] [cited 2022 Jun 23]. Available from: https://purplebooksearch.fda.gov/.
   Google Scholar
• Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021;8:41–61.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Glover J, Greenwald M, et al. FKB327, an Adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Res Ther. 2019;21:281.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an Adalimumab biosimilar, versus reference Adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70:40–48.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of Adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77:914–921.
   PubMed Web of Science ®Google Scholar
• Alten R, Markland C, Boyce M, et al. Immunogenicity of an Adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. Int J Rheum Dis. 2020;23:1514–1525.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Cohen SB, Tony H-P, et al. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. Rheumatology (Oxford). 2021;60:256–262.
   PubMed Web of Science ®Google Scholar
• Müskens WD, Rongen-van Dartel SAA, van Riel PLCM, et al. Does etanercept biosimilar prescription in a rheumatology center bend the medication cost curve? J Rheumatol. 2020;48:1803–1809.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Switching from innovator to biosimilar (subsequent entry) infliximab: an updated review of the clinical effectiveness, cost-effectiveness, and guidelines. [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 [cited 2021 Oct 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK442045/.
   Google Scholar
• Curtis JR, Xie F, Kay J, et al. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019;21:285.
   PubMed Web of Science ®Google Scholar
• Yazdany J, Dudley RA, Lin GA, et al. Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under Medicare Part D. JAMA. 2018;320:931–933.
   PubMed Web of Science ®Google Scholar
• Heidari P, Cross W, Crawford K. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review. Semin Arthritis Rheum. 2018;48:12–21.
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey public use file details-2018. [Internet]. [cited 2020 Dec 12]. Available from: https://meps.ahrq.gov/mepsweb/data_stats/download_data_files_detail.jsp?cboPufNumber=HC-209.
   Google Scholar
• Zhou X-H, Stroupe KT, Tierney WM. Regression analysis of health care charges with heteroscedasticity. J R Stat Soc Ser C Appl Stat. 2001;50:303–312.
   Web of Science ®Google Scholar
• Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation?: comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23:525–542.
   PubMed Web of Science ®Google Scholar